miR-542-3p exerts tumor suppressive functions in neuroblastoma by downregulating survivin

International Journal of Cancer

Volumn 136, Issue 6, 2015, Pages 1308-1320

  Althoff, Kristina ^a,b   Lindner, Sven ^a,b   Odersky, Andrea ^a,b   Mestdagh, Pieter ^c   Beckers, Anneleen ^c   Karczewski, Sarah ^d   Molenaar, Jan J ^e   Bohrer, Anna ^a   Knauer, Shirley ^d   Speleman, Frank ^c   Epple, Matthias ^d   Kozlova, Diana ^d   Yoon, Sena ^f   Baek, Kwanghee ^f   Vandesompele, Jo ^c   Eggert, Angelika ^a   Schramm, Alexer ^a   Schulte, Johannes H ^a,b,d  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f Kyung Hee University   (South Korea)

Author keywords

miR 542 3p; Nanoparticles; Neuroblastoma; Survivin

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; MICRORNA; MICRORNA 542 3P; NANOPARTICLE; SMALL INTERFERING RNA; SURVIVIN; UNCLASSIFIED DRUG; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; MIRN542 MICRORNA, HUMAN; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PATIENT; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; GENE DUPLICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL LINE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PREDICTION; PRIMARY TUMOR; PROTEIN EXPRESSION; PROTEIN RNA BINDING; PROTEIN TARGETING; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; GENETICS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MICE; MICRORNAS; NANOPARTICLES; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS;

EID: 84922242805     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29091     Document Type: Article

References (56)

1. Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. Lancet 2007;369:2106-20.
2. Schwab M, Westermann F, Hero B, et al. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 2003;4:472-80.
3. Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009;27:289-97.
4. Escobar MA, Grosfeld JL, Powell RL, et al. Long-term outcomes in patients with stage IV neuroblastoma. J Pediatr Surg 2006;41:377-81.
5. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-73.
6. Attiyeh EF, London WB, Mosse YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005;353:2243-53.
7. Caron H, van Sluis P, de Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996;334:225-30.
8. Schwab M. [Amplification of N-myc in neuroblastoma: paradigm for clinical use of an oncogene alteration]. Klin Padiatr 1990;202:197-201.
9. Suzuki T, Bogenmann E, Shimada H, et al. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst 1993;85:377-84.
10. Westermark UK, Wilhelm M, Frenzel A, et al. The MYCN oncogene and differentiation in neuroblastoma. Semin Cancer Biol 2011;21:256-66.
11. De Preter K, Vermeulen J, Brors B, et al. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. Clin Cancer Res 2010;16:1532-41.
12. Schramm A, Vandesompele J, Schulte JH, et al. Translating expression profiling into a clinically feasible test to predict neuroblastoma outcome. Clin Cancer Res 2007;13:1459-65.
13. Bown N, Cotterill S, Lastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999;340:1954-61.
14. Combaret V, Brejon S, Iacono I, et al. Determination of 17q gain in patients with neuroblastoma by analysis of circulating DNA. Pediatr Blood Cancer 2011;56:757-61.
15. Islam A, Kageyama H, Takada N, et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000;19:617-23.
16. Lamers F, van der Ploeg I, Schild L, et al. Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe. Endocr Relat Cancer 2011;18:657-68.
17. Schulte JH, Horn S, Schlierf S, et al. MicroRNAs in the pathogenesis of neuroblastoma. Cancer Lett 2009;274:10-5.
18. Suzuki HI, Miyazono K. Dynamics of microRNA biogenesis: crosstalk between p53 network and microRNA processing pathway. J Mol Med 2010;88:1085-94.
19. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215-33.
20. Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev 2009;28:369-78.
21. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med 2009;60:167-79.
22. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005;435:828-33.
23. Mestdagh P, Bostrom AK, Impens F, et al. The miR-17-92 microRNA cluster regulates multiple components of the TGF-beta pathway in neuroblastoma. Mol Cell 2010;40:762-73.
24. O'Donnell KA, Wentzel EA, Zeller KI, et al. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005;435:839-43.
25. Rinaldi A, Poretti G, Kwee I, et al. Concomitant MYC and microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma. Leuk Lymphoma 2007;48:410-2.
26. Schulte JH, Horn S, Otto T, et al. MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer 2008;122:699-704.
27. Mestdagh P, Fredlund E, Pattyn F, et al. MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Oncogene 2010;29:1394-404.
28. Schulte JH, Schowe B, Mestdagh P, et al. Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. Int J Cancer 2010;127:2374-85.
29. De Preter K, Mestdagh P, Vermeulen J, et al. miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples. Clin Cancer Res 2011;17:7684-92.
30. Bray I, Tivnan A, Bryan K, et al. MicroRNA-542-5p as a novel tumor suppressor in neuroblastoma. Cancer Lett 2011;303:56-64.
31. Yoon S, Choi YC, Lee S, et al. Induction of growth arrest by miR-542-3p that targets survivin. FEBS Lett 2010;584:4048-52.
32. Sokolova VV, Radtke I, Heumann R, et al. Effective transfection of cells with multi-shell calcium phosphate-DNA nanoparticles. Biomaterials 2006;27:3147-53.
33. Sokolova V, Knuschke T, Kovtun A, et al. The use of calcium phosphate nanoparticles encapsulating Toll-like receptor ligands and the antigen hemagglutinin to induce dendritic cell maturation and T cell activation. Biomaterials 2010;31:5627-33.
34. Ross RA, Spengler BA, Biedler JL. Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J Natl Cancer Inst 1983;71:741-7.
35. Schweigerer L, Breit S, Wenzel A, et al. Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity. Cancer Res 1990;50:4411-6.
36. Althoff K, Beckers A, Odersky A, et al. MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A. Int J Cancer 2013;133:1064-73.
37. Schulte JH, Marschall T, Martin M, et al. Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma. Nucleic Acids Res 2010;38:5919-28.
38. Schramm A, Schowe B, Fielitz K, et al. Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome. Br J Cancer 2012;107:1409-17.
39. Honda R, Korner R, Nigg EA. Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. Mol Biol Cell 2003;14:3325-41.
40. He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007;447:1130-4.
41. Lujambio A, Calin GA, Villanueva A, et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 2008;105:13556-61.
42. Tarasov V, Jung P, Verdoodt B, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007;6:1586-93.
43. Heukamp LC, Thor T, Schramm A, et al. Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Sci Transl Med 2012;4:141ra91.
44. Molenaar JJ, Domingo-Fernandez R, Ebus ME, et al. LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet 2012;44:1199-206.
45. Weiss WA, Godfrey T, Francisco C, et al. Genome-wide screen for allelic imbalance in a mouse model for neuroblastoma. Cancer Res 2000;60:2483-7.
46. Dai D, Liang Y, Xie Z, et al. Survivin deficiency induces apoptosis and cell cycle arrest in HepG2 hepatocellular carcinoma cells. Oncol Rep 2012;27:621-7.
47. Zhang WH, Poh A, Fanous AA, et al. DNA damage-induced S phase arrest in human breast cancer depends on Chk1, but G2 arrest can occur independently of Chk1, Chk2 or MAPKAPK2. Cell Cycle 2008;7:1668-77.
48. Ghadimi MP, Young ED, Belousov R, et al. Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors. Clin Cancer Res 2012;18:2545-57.
49. Adams RR, Carmena M, Earnshaw WC. Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol 2001;11:49-54.
50. Chen J, Jin S, Tahir SK, et al. Survivin enhances Aurora-B kinase activity and localizes Aurora-B in human cells. J Biol Chem 2003;278:486-90.
51. Giodini A, Kallio MJ, Wall NR, et al. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res 2002;62:2462-7.
52. Chu Y, Yao PY, Wang W, et al. Aurora B kinase activation requires survivin priming phosphorylation by PLK1. J Mol Cell Biol 2011;3:260-7.
53. Lamers F, Schild L, Koster J, et al. Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression. Eur J Cancer 2012;48:763-71.
54. Tolcher AW, Quinn DI, Ferrari A, et al. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol 2012;23:968-73.
55. Yamanaka K, Nakahara T, Yamauchi T, et al. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models. Clin Cancer Res 2011;17:5423-31.
56. Glaros TG, Stockwin LH, Mullendore ME, et al. The "survivin suppressants" NSC 80467 and YM155 induce a DNA damage response. Cancer Chemother Pharmacol 2012;70:207-12.